Biotechnology Business Assets for Sale in Los Angeles, USA
Human cancer gene therapy microbiology technology for sale.
Premium Plan
| Ownership Duration | 10-20 year(s) |
| Industries | Biotechnology |
| Locations | Los Angeles |
| Local Time | 4:24 PM America / Chicago |
| Listed By | Management Member |
| Status | Moderately Active |
Asset Sale
Asking Price:
USD
1 million
(Native Currency: USD 1,000,000)
Reason: We want to sell the technology and help the new owner to patent and market this technology.
We will...
View More
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Not disclosed
User Verification
Documents
ECM for Cancer Gene Therapy
(42.5 KB)
Microvesicles, New Type of Therapeutics
(81.0 KB)
ECM RV in Treatment of a Cancer Patient
(24.0 KB)
Lenti Transduced Microvesicles
(44.7 KB)
Cell Engineering Facility
(444.0 KB)
Business Proposal
(49.5 KB)
Certificate of Incorporation
(2.6 MB)
Assets Description
- We are a new type of biotech company dedicated to human cancer gene therapy and have been working on research projects and the development of human gene therapy vectors.
- Our company has generated various types of DNA nanoparticles for cancer gene therapy.
- Now we have developed new type of RNA nanoparticles called engineered cellular microvesicles (ECM), or RNA microvesicles.
- These are purified cytomox/anti-cancer gene products, such as p16, p53, PTEN, CDC6 shRNA, purified ECM-RV/anti-cancer mRNA, such as p16, p53, CDC6 shRNA, GSDME, EZH2 shRNA,
Klotho, etc.
- The technology includes R&D for the above-mentioned particles and products.
- The R&D & the technology are valued at USD 1 million. Additionally, USD 3-4 million will be required to complete the clinical trials, tests, and marketing.
- The technology is ready and needs to undergo some tests and clinical trials.
- We want to sell the technology and help the buyer to get it patented and market the technology.
- Our company has generated various types of DNA nanoparticles for cancer gene therapy.
- Now we have developed new type of RNA nanoparticles called engineered cellular microvesicles (ECM), or RNA microvesicles.
- These are purified cytomox/anti-cancer gene products, such as p16, p53, PTEN, CDC6 shRNA, purified ECM-RV/anti-cancer mRNA, such as p16, p53, CDC6 shRNA, GSDME, EZH2 shRNA,
Klotho, etc.
- The technology includes R&D for the above-mentioned particles and products.
- The R&D & the technology are valued at USD 1 million. Additionally, USD 3-4 million will be required to complete the clinical trials, tests, and marketing.
- The technology is ready and needs to undergo some tests and clinical trials.
- We want to sell the technology and help the buyer to get it patented and market the technology.
Recent Activity
-
Earlier than 15 daysIndividual Advisor, Mesquite, Financial Consultant connected with the Business
-
Earlier than 15 daysCo-Founder, Conquest Capital, Vancouver, Family Office connected with the Business
-
Earlier than 15 daysDirector, Cosmetics, Bangalore, Corporate Investor / Buyer connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
1 Investor contacted this Business this month.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 122,500+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses